GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (FRA:HBP0) » Definitions » Operating Margin %

Helix BioPharma (FRA:HBP0) Operating Margin % : 0.00% (As of Jan. 2025)


View and export this data going back to . Start your Free Trial

What is Helix BioPharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Helix BioPharma's Operating Income for the three months ended in Jan. 2025 was €-0.87 Mil. Helix BioPharma's Revenue for the three months ended in Jan. 2025 was €0.00 Mil. Therefore, Helix BioPharma's Operating Margin % for the quarter that ended in Jan. 2025 was 0.00%.

The historical rank and industry rank for Helix BioPharma's Operating Margin % or its related term are showing as below:


FRA:HBP0's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -145.17
* Ranked among companies with meaningful Operating Margin % only.

Helix BioPharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Helix BioPharma's Operating Income for the three months ended in Jan. 2025 was €-0.87 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2025 was €-6.71 Mil.


Helix BioPharma Operating Margin % Historical Data

The historical data trend for Helix BioPharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Operating Margin % Chart

Helix BioPharma Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Helix BioPharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Helix BioPharma's Operating Margin %

For the Biotechnology subindustry, Helix BioPharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helix BioPharma's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Operating Margin % falls into.



Helix BioPharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Helix BioPharma's Operating Margin % for the fiscal year that ended in Jul. 2024 is calculated as

Operating Margin %=Operating Income (A: Jul. 2024 ) / Revenue (A: Jul. 2024 )
=-6.211 / 0
= %

Helix BioPharma's Operating Margin % for the quarter that ended in Jan. 2025 is calculated as

Operating Margin %=Operating Income (Q: Jan. 2025 ) / Revenue (Q: Jan. 2025 )
=-0.867 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Helix BioPharma  (FRA:HBP0) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Helix BioPharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Helix BioPharma Business Description

Traded in Other Exchanges
Address
40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4
Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.

Helix BioPharma Headlines

No Headlines